

VetStem, Inc. Achieves Industry Leading Stem Cell Processing Milestone

Leading regenerative medicine company, VetStem, Inc., has processed over 17,000 patient samples resulting in nearly 43,000 stem cell treatments.

POWAY, CA, UNITED STATES, September 22, 2026 /EINPresswire.com/ -- Leading regenerative veterinary medicine company [VetStem, Inc.](#) is proud to announce a significant milestone in its continued commitment to advancing animal health. The company has now processed more than 17,000 patient samples, resulting in nearly 43,000 stem cell treatments for animals across the United States and Canada. As a pioneer in regenerative veterinary medicine, the San Diego-based company has been providing stem cell processing services to veterinarians and their patients for more than 20 years.



VetStem's patented technology allows for the [isolation and concentration](#) of regenerative cells from a patient's own adipose (fat) tissue, providing veterinarians with an additional treatment option for a variety of orthopedic and degenerative conditions. VetStem Cell Therapy is primarily used to treat musculoskeletal conditions such as osteoarthritis and injuries to tendons and ligaments in dogs, cats, and horses. In addition to domestic animals, VetStem has worked with multiple exotic animal organizations to provide stem cell therapy for several exotic species.

"Surpassing 17,000 processed patient samples and nearly 43,000 stem cell treatments is an incredible milestone for VetStem," said Dr. Bob Harman, CEO and Founder of VetStem. "These numbers represent thousands of animals that have received regenerative medicine and the veterinarians who have trusted VetStem to support their patients. After more than 20 years, we remain committed to advancing regenerative veterinary medicine and expanding the ways these therapies can help improve the lives of animals."

As VetStem looks toward the future, the company remains committed to advancing regenerative



These numbers represent thousands of animals that have received regenerative medicine and the veterinarians who have trusted VetStem to support their patients."

Dr. Bob Harman, VetStem CEO

veterinary medicine through continued research, innovation, and collaboration with the veterinary community. With more than two decades of experience and nearly 43,000 stem cell treatments, VetStem continues to build on its clinical experience and expertise to provide veterinarians with innovative treatment options for their patients.

[About VetStem, Inc.](#)

VetStem is a veterinarian-led company that was formed in 2002 to bring regenerative medicine to the profession. This

privately held biopharmaceutical enterprise, based near San Diego, California, currently offers veterinarians an autologous stem cell processing service (from patients' own fat tissue) among other regenerative modalities. With unique expertise acquired over the past 20+ years and thousands of treatments by veterinarians for joint, tendon and ligament issues, VetStem has made regenerative medicine applications a therapeutic reality. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. In addition to its own portfolio of patents, VetStem holds exclusive global veterinary licenses to a large portfolio of issued patents in the field of regenerative medicine.

Kristi Hauta, Director of Commercial Operations

VetStem, Inc.

+1 858-748-2004

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/943992693>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.